Table 2.

Patient Demographics by Study Group and Treatment Cohort

	Group A Normal liver function	Group B Mild liver dysfunction		Group C Moderate liver dysfunction		Group D Severe liver dysfunction
Starting dose of Pazopanib (mg)	800	400	800	200	400	100	200
Number of patients	23	9	14	13	71	13	19
Median Age (range)	58 (24–78)	56 (51–66)	57 (47–78)	58 (36–76)	65 (52–73)	56 (31–70)	51 (39–78)
Gender (number and %
Male	10 (43%)	3 (33%)	8 (57%)	4 (31%)	7 (100%)	9 (69%)	12 (63%)
Female	13 (57%)	6 (67%)	6 (43%)	9 (69%)		4 (31%)	7 (37%)
Race (Number and %)
White	22 (96%)	7 (78%)	12 (86%)	11 (84%)	2 (29%)	10 (76%)	11 (58%)
Black	1 (4%)	1 (11%)		1 (8%)	1 (14%)	1 (8%)	5 (26%)
Asian		1 (11%)	2 (14%)	1 (8%)	4 (57%)	1 (8%)	2 (11%)
Native Hawaiian or Other Pacific Islander						1 (8%)
Unknown							1 (5%)
Ethnicity (Number and %)
Not Hispanic or Latino	22 (96%)	9 (100%)	13 (93%)	9 (69%)	5 (72%)	13 (100%)	15 (79%)
Hispanic or Latino			1 (7%)	4 (31%)	1 (14%)		4 (21%)
Unknown	1 (4%)				1 (14%)
KPS2 Score (Number and %)
60	1 (4%)	1 (11%)	2 (14%)	1 (8%)	1 (14%)	3 (23%)	5 (26%)
70–80	9 (39%)	5 (56%)	2 (14%)	6 (46%)	5 (72%)	10 (76%)	13 (68%)
90–100	13 (57%)	3 (33%)	10 (72%)	6 (46%)	1 (14%)		1 (6%)
Baseline Abnormalities
(AEs)
(Number and %)
Grade 1	95 (63%)	44 (60%)	72 (64%)	106 (67%)	39 (47%)	81 (50%)	133 (65%)
Grade 2	48 (32%)	22 (30%)	32 (28%)	44 (28%)	33 (40%)	57 (35%)	45 (22%)
Grade 3	7 (5%)	7 (9%)	9 (8%)	9 (5%)	11 (13%)	20 (12%)	21 (10%)
Grade 4		1 (1%)				5 (3%)	5 (3%)
Type of Primary Tumor/Hematologic Malignance (N)
Bile Duct				1		1	1
Breast		4				1
Colon/ Rectum	6	2	6	9	3	5	10
Liver	1	2	3	1	2	2	2
Lung	1			1		2
Pancreas	1		2	1		1	1
Other (n=26)

¹One patient was not treated; there is no weight information for this patient.

²Karnofsky Performance Status